COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Reports Second Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
24/07/2025
Conference Call and Webcast scheduled for tomorrow, July 25, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign (TM [...]
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
24/07/2025
Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs [...]
CooperCompanies Announces Release Date for Third Quarter 2025
24/07/2025
SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at [...]
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
24/07/2025
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ” or “ Rakovina ”) a biopharmaceutical company advancing cancer therapies through artificial [...]
Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow
24/07/2025
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Algernon Announces Closing of the Private Placement Financing
24/07/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: [...]
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
24/07/2025
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Natural Brain Support Without the Crash: Lives Potions Introduces Plant-Based Cognitive Enhancement
24/07/2025
This Herbal Brain Booster supports short-term focus and long-term brain health, offering calm, clean mental energy without jitters or burnout Brooklyn, NY, July 24, 2025 (GLOBE NEWSWIRE) -- Lives Potions is making waves [...]
Guerbet : Chiffre d’affaires du 1er semestre 2025
24/07/2025
Chiffre d’affaires du 1 er semestre 2025 Activité semestrielle Un chiffre d’affaires à mi-exercice de 387,8 M€, marquant un repli de 5,4% à TCC 1 et périmètre comparable 2 très largement dû à la baisse d’activité en [...]
Guerbet : H1 2025 revenue
24/07/2025
H1 2025 revenue First-half activity H1 revenue of €387.8 million, down 5.4% at CER 1 and like-for-like 2 largely due to the fall in activity in France Sales at CER and on a like-for-like basis increased in EMEA [...]
Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics
24/07/2025
BUFFALO, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Omniscient (o8t®), the global leader in connectomics, is proud to announce a groundbreaking partnership with The Jacobs Institute, Inc. (JI), a one-of-a-kind non-profit [...]
Fairhaven Health Strengthens Women’s Health Commitment Beyond Fertility
24/07/2025
MIDDLETOWN, Conn., July 24, 2025 (GLOBE NEWSWIRE) -- As the world honors World IVF Day, Fairhaven Health — a company long recognized by reproductive health professionals for its fertility-focused supplements — is [...]
Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées
24/07/2025
Cabometyx ® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la [...]
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
24/07/2025
Cabometyx ® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non- [...]
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
24/07/2025
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs) RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it [...]
Solésence To Report Second Quarter 2025 Financial Results and Host a Conference Call
24/07/2025
ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
24/07/2025
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today [...]
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
24/07/2025
BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
24/07/2025
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages